ArticleFrontiers in pharmacology2026
Altered expression of MX2 and SAMD4A in PBMCs predicts early treatment responses in HBeAg-positive chronic hepatitis B patients during Peg-IFN-α therapy.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic Hepatitis B (CHB) is a major global health concern. This study aimed to evaluate whether myxovirus resistance 2 (MX2) and sterile alpha motif domain containing 4A (SAMD4A) mRNA levels in peripheral blood mononuclear cells (PBMCs) can predict early treatment responses to pegylated interferon-alpha (Peg-IFN-α) in hepatitis B e antigen (HBeAg)-positive CHB patients. Methods: This prospective cohort study enrolled HBeAg-positive CHB patients who received Peg-IFN-α for 48 weeks. Patients were classified into virological response (VR; HBV DNA <50 IU/mL at week 48) and non-virological response (NVR) groups, and into serological response (SR; HBeAg seroconversion at week 48) and non-serological response (NSR) groups. MX2 and SAMD4A mRNA levels in PBMCs were measured by quantitative real-time PCR (qRT-PCR) at weeks 0, 12, and 24. Spearman's rank correlation analysis was performed to evaluate the relationships between gene expression levels and declines in HBeAg and HBV DNA. Univariate and multivariate logistic regression analyses were conducted to identify independent predictors of VR and SR, and predictive performance was assessed using receiver operating characteristic (ROC) curves with calculation of the area under the curve (AUC). Results: At week 48, the VR and SR rates were 64.63% and 39.02%, respectively. Dynamic changes in MX2 and SAMD4A mRNA levels differed significantly between the VR and NVR groups and between the SR and NSR groups. Both MX2 and SAMD4A mRNA levels at weeks 12 and 24 were positively correlated with concurrent reductions in HBeAg and HBV DNA. Notably, early upregulation of both genes at week 12 was significantly associated with subsequent reductions in HBeAg and HBV DNA observed at week 24. Multivariate analysis identified MX2 and SAMD4A as independent predictors of both VR and SR at weeks 12 and 24. At week 24, the AUC values of MX2 were 0.7567 for VR and 0.8421 for SR, while those of SAMD4A were 0.8549 for VR and 0.8717 for SR. Conclusion: MX2 and SAMD4A are important biomarkers for early treatment responses to Peg-IFN-α in HBeAg-positive CHB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.